



Pauline TORTAJADA; Rodrigue DOAMBA; Luis CANO; Daniel CHERQUI; René ADAM; Antonio SA CUNHA; Daniel AZOULAY; **Eric VIBERT; Nicolas GOLSE** Hepatobiliary Centre - Paul Brousse Hospital, Villejuif, France.


INTRODUCTION

- Liver transplantation (LT) is the ideal hepatocellular for treatment carcinoma (HCC).
- Liver resection (LR) is a curative HCC selected treatment for in patients in the context of organ shortage.
- The recurrence rate remains high (almost 2/3 of patients recur at 5 years).

AIM

establish a preoperative score • To predictive of recurrence after LR to improve the decision-making process between LR and LT.





METHOD

- Single-centre retrospective study from Jan 2015 to Dec 2018 from prospective database
- Inclusion criteria:
- LR for HCC with AFP score $\leq 2^{1}$
- Preoperative percutaneous with elastometry measurement FibroScan Touch502 probe (Echosens, Paris, France)
- Post-operative follow-up: every 3-4 months, including liver tests, AFP, CT or MRI.

Recurrence: defined as appearance of a typical HCC lesion on imaging, validated in multidisciplinary tumor bord.

HEPATIC ELASTOMETRY AND RISK OF RECURRENCE AFTER HCC RESECTION

score: univariate Cox Recurrence regression and multivariate analysis with combination plot, selection of optimal thresholds (ROC curves), testing on a validation cohort using the Bootstrap method.

CONCLUSIONS

- Recent cohort from an expert centre.
- Recurrence rate comparable to literature.
- Elastometry in a population with HCC in the criteria of transplantation can predict the risk of recurrence.
- This work is part of the long-standing debate between LR and LT and could help in the therapeutic choice (LR vs. LT).
- Further work for validation on a larger prospective cohort.

¹ Duvoux C, Roudot–Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology. 2012 Oct;143(4):986-994.e3.





analysis		Multiv	Multivariate analysis		
CI	p value	HR	CI	p value	
1.00-1.1	0.02	0.92	1.02-1.14	0.003	
0.99-1.15	0.05	0.94	0.94-1.19	0.33	
0.61-0.98	0.03	0.88	0.65-1.18	0.40	
2.84-1224	0.008	0.01	2.42-1563	0.01	
1.00-1.00	0.006	1.00	0.82-1.20	0.34	
1.00-1.00	0.003	1.00	0.99-1.00	0.24	
1.00-1.05	0.03	0.94	1.02-1.09	<0.01	
1.16-2.32	0.004	0.43	1.57-3.29	<0.01	

HR indicates hazard ratio; CI, confidence interval; ASAT, Aspartate transaminase; ALAT, Alanine tran saminase; GGT, Gamma-glutamyltransferase; ALKP, Alkaline phosphatase; INR, international norma

INR > 1.22	Elastometry > 11.2	Diameter nodule >2.7	Total
1	1	1	4
0	0	0	0

REFERENCES

CONTACT INFORMATION

Pauline Tortajada, M.D.

pauline.tortajada@aphp.fr







